FindTrial
Sign In

SEL

DRUG6 trials

Sponsors

Gilead Sciences

Conditions

Diabetic Kidney DiseaseNon-Alcoholic Steatohepatitis (NASH)Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)

Phase 2

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
CompletedNCT02466516
Gilead SciencesNon-Alcoholic Steatohepatitis (NASH)
Start: 2015-06-08End: 2016-10-11Updated: 2019-06-26
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
CompletedNCT02781584
Gilead SciencesNonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Start: 2016-06-13End: 2020-12-17Updated: 2022-03-16
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
CompletedNCT03449446
Gilead SciencesNonalcoholic Steatohepatitis
Start: 2018-03-21End: 2019-11-19Updated: 2020-12-03
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
CompletedNCT04026165
Gilead SciencesDiabetic Kidney Disease
Start: 2019-07-24End: 2021-09-03Updated: 2022-12-21

Phase 3

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
TerminatedNCT03053050
Gilead SciencesNonalcoholic Steatohepatitis
Start: 2017-02-13End: 2019-06-19Updated: 2020-06-29
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
TerminatedNCT03053063
Gilead SciencesNonalcoholic Steatohepatitis
Start: 2017-01-30End: 2019-05-06Updated: 2020-05-07

Related Papers

Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis
Diabetes Obesity and Metabolism2025-05-15
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.
2025-01-019 citations
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.
2024-08-0728 citations
Selonsertib in Patients with Diabetic Kidney Disease
Journal of the American Society of Nephrology2024-07-1712 citations
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
2022-01-2216 citations
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
2022-01-0632 citations
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Hepatology Communications2021-05-1231 citations
A computational analysis of the binding free energies of apoptosis signal-regulating kinase 1 inhibitors from different chemotypes
Molecular Simulation2021-05-123 citations
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
2020-12-0881 citations
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
2020-03-06352 citations
IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials
2019-06-011 citations
IDDF2019-ABS-0133 Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib
2019-06-01
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
2019-02-1674 citations
Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
2019-01-1135 citations
An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications
Clinical Liver Disease2018-04-0139 citations